20107 results for «»
20107 results
Late-breaking evidence in structural and coronary interventions - Part 2
16 Nov 2025 – From PCR London Valves 2025
This session presents the latest data from pivotal late-breaking trials in interventional cardiology. Highlights include one-year results from the ADALA trial, first-in-man use of the Vivasure PerQseal Elite for large hole arterial closure, two-year outcomes of the DragonFly system in China, six-month European outcomes, and insights...
How do we meet the needs of women with heart valve disease?
27 Mar 2026 – From PCR London Valves 2025
In this interview, Ellen Ross and Marta Sitges discuss a recent initiative from Global Heart Hub - a patient association - which examined the realities faced by women living with heart valve disease. They outline the gaps identified, the call to action that followed, and how...
What are the key considerations when managing combined mitral and tricuspid regurgitation?
17 Feb 2026 – From PCR London Valves 2025
Fabien Praz and Neil Fam talk about the management of patients with combined mitral and tricuspid regurgitation, who are often elderly with heart failure and multiple comorbidities. Careful assessment—including echocardiography, hemodynamics, and sometimes CT—is crucial to identify the dominant lesion. Surgery is preferred if feasible, but...
One-year results from the ADALA trial
16 Nov 2025 – From PCR London Valves 2025
Left atrial appendage (LAA) closure is a new focus at this year’s PCR London Valves Course, and, in this interview, Xavier Freixa and Christopher Allen discuss the ADALA trial and its impact on post-occlusion management.
The study compared three months of low-dose DOAC with three months of...
Is iatrogenic atrial septum defect closure a necessary procedure?
17 Nov 2025 – From PCR London Valves 2025
Philipp Lurz and Saibal Kar discuss iatrogenic atrial septal defects from transseptal procedures. Small ones usually close on their own, while large defects causing significant shunting need closure to prevent right heart overload. Some moderate defects may be beneficial by decompressing the left atrium, so closure...
PARTNER 3 — 7-year follow-up: what it means for low-risk patients
16 Nov 2025 – From PCR London Valves 2025
Philippe Généreux and Philippe Pibarot discuss the long-term findings from PARTNER 3 and their practical implications for patient care.
They review the 7-year comparison of transfemoral TAVR versus surgical aortic-valve replacement in symptomatic patients with severe aortic stenosis who are at low surgical risk, and why the...
Should we consider TTVR in patients with straightforward anatomy who are eligible for T-TEER?
17 Nov 2025 – From PCR London Valves 2025
Lukas Stolz and Rebecca Hahn discuss advances in transcatheter tricuspid valve intervention, emphasising that reducing tricuspid regurgitation (TR) to mild levels is key for improving patient outcomes, including mortality and heart failure hospitalisations. Decision-making between transcatheter edge-to-edge repair (T-TEER) and transcatheter tricuspid valve replacement (TTVR) depends...
TARGET study interim results: safety and performance of Cardiovalve replacement system for tricuspid regurgitation
16 Nov 2025 – From PCR London Valves 2025
Georg Nickenig and Christopher Allen discuss transcatheter replacement for the tricuspid valve and a dedicated transfemoral device in this interview, focusing on the TARGET study.
TARGET set out to answer two questions: can tricuspid regurgitation (TR) be reduced to mild or zero, and what are the safety...
TAVI for aortic regurgitation in high surgical risk: outcomes in 700 patients from ALIGN-AR
12 Feb 2026 – From PCR London Valves 2025
Christopher Allen and Raj Makkar sit down to review the ALIGN-AR trial and its implications for treating native aortic regurgitation.
ALIGN-AR was a pivotal, single-arm, multicenter investigational study designed to evaluate a dedicated transcatheter solution in patients with moderate-to-severe native AR who were considered high risk for...
The D-PACE scoring system Prediction of high-grade conduction disturbances after TAVI
16 Nov 2025 – From PCR London Valves 2025
Michael Joner and Francesco Saia discuss the newly developed D-PACE Score, a tool designed to predict delayed AV block occurring more than 24 hours after TAVI—an unmet clinical need given that current risk models focus mainly on early events. The next steps aim to refine the...
Why is TAVI a different procedure in patient with pure aortic regurgitation?
15 Nov 2025 – From PCR London Valves 2025
In this video, Juan Granada, Michael Borger and Joao Cavalcante highlight that aortic insufficiency differs from aortic stenosis and is often underestimated. Early, comprehensive evaluation and imaging are crucial. Surgery is standard for severe cases, while TAVI with dedicated devices is an option for high-risk patients.
This...
What are the key considerations for transcatheter mitral paravalvular leak management?
18 Nov 2025 – From PCR London Valves 2025
Nina Wunderlich and Patrick Calvert discuss mitral paravalvular leaks, which are relatively common. Percutaneous closure is now the default approach, and imaging is central to success: detailed pre-procedural assessment, 3D TOE during the procedure, and careful planning of transseptal puncture.
This interview was filmed at PCR London...
What are the key steps in pre procedural assessment for successful LAA closure?
16 Nov 2025 – From PCR London Valves 2025
Lorenz Räber and Kasper Korsholm highlight why pre-procedural imaging—particularly cardiac CT—has become essential for successful left atrial appendage occlusion (LAAO). They explain that the LAA is highly variable between patients, making detailed planning crucial for safety, device selection, and optimal procedural results.
This interview was filmed at...
How to manage patients with aortic stenosis and coronary artery disease?
04 Mar 2026 – From PCR London Valves 2025
Tiffany Patterson and Davide Capodanno address the increasingly common scenario of managing coronary artery disease (CAD) in patients undergoing TAVI. With up to half of TAVI candidates presenting with CAD, they highlight new evidence from NOTION-3 showing that revascularization reduces major adverse cardiac events. The takeaway:...
When the first TAVI fails: no panic, just planning
19 Jan 2026
An 81-year-old man with history of severe aortic stenosis previously treated with a balloon-expandable transcatheter valve was referred for progressive exertional dyspnea due to bioprosthetic valve degeneration.
How would you treat this patient?
Author
Spotlight on a selection of top Late-breaking Trials presented at PCR London Valves 2025
17 Nov 2025
View a snapshot of the results of these 4 trials in valvular and structural interventions presented in London during this year's Heart Team Course!
Validation of intravascular ultrasound-defined optimal stent expansion criteria for favorable 1-year clinical outcomes
17 Nov 2025
This individual patient data analysis of the three largest RCTs evaluating IVUS-guided stent optimisation showed that an MSA > 5.5 mm2 was associated with reduced TVF at one year.
Reviewer
Reviewer
PCR: Collaborative, inclusive and global
15 Nov 2025 – From PCR London Valves 2025
At PCR, collaboration and inclusion are at the heart of everything we do.
Together, we create an environment where expertise is shared, talents complement each other, and diversity becomes a strength. It is this collective spirit that drives interventional cardiology forward and inspires innovation every day.
During PCR London...
Meril Life Sciences presents one-year outcomes from the LANDMARK randomized controlled trial at PCR London Valves 2025
16 Nov 2025
GulfPCR-GIM 2025: the Training Programme is now available!
